sGC STIMULATORS

A compound of Formula I, or a pharmaceutically acceptable salt thereof,

• wherein:
• the core formed by rings E and A along with the substituents (Jc)p is represented by the following formula:
• wherein the C atom with a symbol * represents the attachment point to the ring containing G, Z, and Q;
• and the C atom with a symbol ** represents the point of attachment of the 2 instances of J;
• W is either
• i) absent, with JB connected directly to the carbon atom bearing two J groups, each J is independently selected from hydrogen or methyl, n is 1 and JB is a C1-7 alkyl chain optionally substituted by up to 9 instances of fluorine;
• or
• ii) a ring B that is a phenyl, a C3-7 cycloalkyl ring or a 5 or 6-membered heteroaryl ring, containing 1 or 2 ring nitrogen atoms;
• wherein when ring B is the phenyl or 5 or 6-membered heteroaryl ring;
• each J is independently selected from hydrogen or methyl;
• n is 2 or 3;
• and each JB is independently selected from halogen, —CN, a C1-6 aliphatic, —ORB or a C3-8 cycloaliphatic ring;
• and
• wherein when ring B is the C3-7 cycloalkyl ring;
• each J is hydrogen;
• n is 2 or 3 and each JB is independently selected from halogen, —CN, a C1-6 aliphatic or —ORB1;
• wherein each JB that is a C1-6 aliphatic and each JB that is a C3-8 cycloaliphatic ring is optionally and independently substituted with up to 3 instances of R3;
• each RB is independently selected from a C1-6 aliphatic or a C3-8 cycloaliphatic ring;
• said RB optionally and independently substituted with up to 3 instances of R3a;
• each RB1 is independently selected from hydrogen, a C1-6 aliphatic or a C3-8 cycloaliphatic ring;
• wherein each of said C1-6 aliphatic and each of said C3-8 cycloaliphatic ring is optionally and independently substituted with up to 3 instances of R3b;
• each R3, R3a and R3b is, in each instance, independently selected from halogen, —CN, C1-4 alkyl, C1-4 haloalkyl, —O(C1-4 alkyl) or —O(C1-4 haloalkyl);
• each JC is independently selected from hydrogen, halogen, C1-4 aliphatic, C1-4 alkoxy or —CN;
• wherein each said C1-4 aliphatic and C1-4 alkoxy is optionally and independently substituted by up to 3 instances of C1-4 alkoxy, C1-4 haloalkoxy, —OH or halogen;
• Q, G, and Z are each independently N, S. or O, wherein at least two of Q, G, and Z are N;
• q is 0, 1, or 2;
• R10 is C1-6 alkyl optionally and independently substituted with 0-3 occurrences of R15, phenyl optionally and independently substituted with 0-3 occurrences of R15, 5- or 6-membered heteroaryl optionally and independently substituted with 0-3 occurrences of R15, C3-8 cycloalkyl optionally and independently substituted with 0-3 occurrences of R15 or 3-8 membered heterocyclyl optionally and independently substituted with 0-3 occurrences of R15;
• wherein each of said 5- to 6-membered heteroaryl ring and each of said 3-8 membered heterocyclyl contains up to 3 ring heteroatoms independently selected from N, O or S;
• R11 is H, —NRa2Rb2, —C(O)NRa2Rb2, —C(O)R15a, —SO2Rb2, —SRb2, halo, —OCF3, —CN, hydroxyl, C2-6 alkenyl optionally and independently substituted with 0-2 occurrences of Rb2, C2-6 alkynyl optionally and independently substituted with 0-2 occurrences of Rb2;
• C1-6 alkyl optionally and independently substituted with 0-5 occurrences of R15, C1-6 alkoxy optionally and independently substituted with 0-5 occurrences of R15, phenyl optionally and independently substituted with 0-3 occurrences of R15, 5- to 6-membered heteroaryl optionally and independently substituted with 0-3 occurrences of R15, C3-8 cycloalkyl optionally and independently substituted with 0-3 occurrences of R15 or 3-8 membered heterocyclyl optionally and independently substituted with 0-3 occurrences of R15;
• wherein each of said 5- to 6-membered heteroaryl and each of said 3-8 membered heterocyclyl contains up to 3 ring heteroatoms independently selected from N, O or S;
• or
• when R10 is a substituent of Z, R10 and R11, taken together with Z and the carbon to which R11 is attached, form a 3-10 membered heterocyclic ring optionally and independently substituted with 0-3 occurrences of R15;
• wherein each of said 3-10 membered heterocyclyl contains up to 3 ring heteroatoms independently selected from N, O or S;
• R15 is halo, —ORb2, —SRb2, —NRa2Rb2, —C(O)Rb2, —C(O)NRa2Rb2, —NRb2C(O)ORb2, —OC(O)NRa2Rb2, C2-4 alkenoxy, C3-8 cycloalkyl optionally and independently substituted with 0-3 occurrences of R18, phenyl optionally and independently substituted with 0-3 occurrences of R18, 5- or 6-membered heteroaryl optionally and independently substituted with 0-3 occurrences of R18 or 3-10 membered heterocyclyl optionally and independently substituted with 0-3 occurrences of R18;
• wherein each of said 5- or 6-membered heteroaryl ring and each of said 3-10 membered heterocyclyl contains up to 3 ring heteroatoms independently selected from N, O or S;
• R15a is C3-8 cycloalkyl optionally and independently substituted with 0-3 occurrences of R18, phenyl optionally and independently substituted with 0-3 occurrences of R18, 5- or 6-membered heteroaryl optionally and independently substituted with 0-3 occurrences of R18 or 3-10 membered heterocyclyl optionally and independently substituted with 0-3 occurrences of R18;
• wherein each of said 5- or 6-membered heteroaryl ring and each of said 3-10 membered heterocyclyl contains up to 3 ring heteroatoms independently selected from N, O or S;
• each R18 is independently selected from halo, hydroxyl, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl or phenyl;
• Ra2 is hydrogen, —C(O)Rb2, C1-6 alkyl or C1-6 haloalkyl;
• and
• Rb2 is hydrogen, C1-6 alkyl or C1-6 haloalkyl.